Vildagliptin | place in therapy review to therapy. As the majority of the costs of managing diabetes are attributable to managing complications, this evidence would also be important in assessing the potential economic impact of the agent. In summary, vildagliptin has shown evidence of improved glycemic control and a potentially favorable tolerability profile in adult patients with type 2 diabetes. This has potential for important clinical and/or economic benefits in the management of diabetes, as improved glycemic control is likely to reduce the risk of complications and thus improve resource utilization. Vildagliptin could be a useful option for use in combination therapy in patients with type 2 diabetes. Acknowledgements The authors declare that they have no conflicts of interest. References AACE (American Association of Clinical Endocrinologists). Diabetic Guidelines. Endocrine Practice. 2002;8(Suppl 1):41–65. AACE (American Association of Clinical Endocrinologists). State of Diabetes in America. Available at: http://www.stateofdiabetes.com (accessed November 8, 2005). ACCORD Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–2559. ADA (American Diabetes Association) and NIDDKD (National Institute of Diabetes, Digestive and Kidney Diseases). The prevention or delay of type 2 diabetes. Diabetes Care. 2002;25:742–749. ADA (American Diabetes Association). Standards of medical care in diabetes. Diabetes Care. 2005;28(Suppl. 1):S4–S36. Ahrén B, Landin-Olsson M, Jansson P-A, et al. The DPPIV inhibitor, LAF237, reduces fasting and postprandial glucose in subjects with type 2 diabetes over a 4 week period by increasing active GLP-1, sustaining insulin and reducing glucagon. Diabetes. 2003;52 (Suppl. 1):A15. Abstract 65-OR. Ahrén B, Mills D, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin- treated patients with type 2 diabetes. Diabetes Care. 2004a;27:2874–2880. Ahrén B, Landin-Olsson M, Jansson P-A, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagons levels in type 2 diabetes. J Clin Endocrinol Metab. 2004b;89:2078–2084. Ahrén B, Gomis R, Mills D, Schweizer A. The DPP-4 inhibitor, LAF237, improves glycemic control in patients with type 2 diabetes (T2DM) inadequately treated with metformin. Presented at the American Diabetes Association Scientific Sessions, 2004c. Abstract 354-OR. Available at: http://scientificsessions. diabetes.org/Abstracts/index.cfm (accessed December 12, 2005). Ahrén B, Winzell MS, Burkey B, Hughes TE. Beta-cell expression of a dominant-negative hepatocyte nuclear factor (HNF)-1alfa compromises the ability of DPP-4 inhibition to elicit a long-term augmentation of insulin secretion in mice. Presented at the American Diabetes Association Scientific Sessions, 2005a. Abstract 1559-P. Available at: http://scientificsessions.diabetes.org/ Abstracts/index.cfm (accessed December 12, 2005). Ahrén B, Foley JE, Pacin G, Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care. 2005b;28:1936–1940. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298:194–206. Anon. New Galvus® clinical data reinforces efficacy profile; safety up- date provided to regulatory agencies. Available at http://cws.huginonline. com/N/134323/PR/200711/1166139_5_2.html (accessed November 12, 2007). 28 Barilla D, He Y, Balez S, et al. No pharmacokinetic interactions or acute clinical safety issues preclude combination of the DPP-4 inhibitor LAF237 with glyburide. Presented at the American Diabetes Association Scientific Sessions, 2004. Abstract 1967-PO. Available at: http://scientificsessions.diabetes.org/ Abstracts/index.cfm (accessed December 12, 2005). Baron MA, Rosenstock J, Bassiri B, et al. Efficacy of vildagliptin combined with pioglitazone in patients with type 2 diabetes. Presented at the European Association for the Study of Diabetes Annual Meeting, 2006. Abstract 0801. Available at: http://www.easd.org/ (accessed October 11, 2007). Bartnik M, Malmberg K, Norhammar A, Tenerz A, Ohrvik J, Rydén L. Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J. 2004;25:1990–1997. Bloomgarden ZT. Type 2 diabetes in the young: the evolving epidemic. Diabetes Care. 2004;27:998–1010. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007;30:890–895. Brandt I, Joossens J, Chen X, et al. Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by vildagliptin ((2S)-{[3-hydroxyadamantan-1-yl)amino]acetyl]}- pyrrolidine-2-carbonitrile). Biochem Pharmacol. 2005;70:134–143. Burkey B, Li X, Bolognese L, et al. Combination treatment of a DPP-IV inhibitor NVP-LAF237 with pioglitazone completely normalized glucose tolerance in adult obese Zucker rats. Diabetes. 2002;51(Suppl. 2):A338. Abstract 1383-P. Burkey BP, Li X, Bolognese L, et al. Acute and chronic effects of the incretin enhancer vildagliptin in insulin resistant rats. J Pharmacol Exp Ther. 2005;315:688–695. CDC (Centers for Disease Control and Prevention). Diabetes Projects, 2005b. Available at: http://www.cdc.gov/diabetes/projects/cda2.htm (accessed November 7, 2005). CDC (Centers for Disease Control and Prevention). Fact Sheet. SEARCH for Diabetes in Youth, 2005a. Available at: http://www.cdc.gov/diabetes/pubs/pdf/ search.pdf (accessed November 7, 2005). CDC (Centers for Disease Control and Prevention). National Diabetes Fact Sheet, United States, 2003. General Information. Available at: http://www.cdc. gov/diabetes/pubs/pdf/ndfs_2003.pdf (accessed November 7, 2005). Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359: 2072–2077. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22:233–240. Dardik B, Schwartzkopf C, Stevens D, et al.The dipeptidyl peptidase IV inhibitor NVP-LAF237 improves metabolic control in diabetic and nondiabetic cynomolgus monkeys. Diabetes. 2003a;52(Suppl.1):A322. Abstract 1391-P. Dardik B, Valentin M, Schwartzkopf C, et al. NVP-LAF237, a dipeptidyl peptidase IV inhibitor, improves glucose tolerance and delays gastric emptying in obese insulin resistant cynomolgus monkeys. Diabetes. 2003b;52 (Suppl.1):A322. Abstract 1392-P. DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161:397–405. Dejager S, Razac S, Foley JE, Schweizer A. Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo- controlled, multiple-dose study. Horm Metab Res. 2007a;39:218–223. Dejager S, Schweizer A, Couturier A, Pratley RE. Achievement of glycaemic targets with vildagliptin. Presented at the European Association for the Study of Diabetes Annual Meeting, 2007b. Abstract 0885. Available at: http://www.easd.org/ (accessed October 11, 2007). Duttaroy A, Voelker F, Merriam K, Zhang X, Ren X, Burkey B. The DPP-4 inhibitor vildagliptin increases pancreatic beta-cell neogenesis and decreases apoptosis. Presented at the American Diabetes Association Scientific Sessions, 2005a. Abstract 572-P. Available at: http://scientificsessions. diabetes.org/Abstracts/index.cfm (accessed December 12, 2005). © 2008 Core Medical Publishing Limited